文献速递泌尿男性生殖肿瘤

将低级别前列腺癌重新归类为癌前病变后的前列腺癌死亡率建模分析

Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous.
PubMed 文献 · JAMA Oncol · 2026-01-01

该决策分析模型基于2020至2025年美国人群与临床数据,评估将GG1前列腺癌重新归类为癌前病变对前列腺癌死亡率的影响。模型预测,重新归类带来的筛查率提升所避免的年度死亡数(2835例)是主动监测依从性下降所增加死亡数(452例)的6倍,净效应为死亡率下降。

要点

  • 将GG1前列腺癌重新归类为癌前病变,模型预测年度避免死亡数约为增加死亡数的6倍(2835 vs 452)。
  • 即使主动监测进展率增加50%、不依从率翻倍且筛查率仅绝对增加10%,年度死亡仍净减少近500例。
  • 基础案例下,筛查率绝对增加仅3%即可实现死亡率净下降。

核心结论

  • 将GG1前列腺癌重新归类为癌前病变,模型预测前列腺癌死亡数净减少。

研究设计与样本

  • 2025年创建的决策分析模型,使用2020至2025年发表的美国人群与临床数据估计GG1患者数及考虑PSA筛查的男性数。

主要发现

  • 基础案例中,重新归类导致年度避免的前列腺癌死亡数为2835例,而增加的前列腺癌死亡数为452例,避免数是增加数的6倍。
  • 多种情景修改模型输入均未改变结论;例如主动监测进展率增加50%、不依从率翻倍且筛查率绝对增加10%时,年度死亡仍减少近500例。
  • 基础案例下,筛查率绝对增加仅3%即可实现死亡率净下降。

临床怎么用

  • 模型提示去除GG1前列腺癌的「癌」标签可能通过减少过度诊断担忧、提高筛查率而净降低前列腺癌死亡率。
  • 反对去除标签者需论证重新归类对筛查率影响接近零,或其他危害超过死亡率下降的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It has been proposed that grade group (GG) 1 prostate cancer should no longer be defined as cancer but as a precancerous condition. One argument raised by critics is this would decrease adherence with essential monitoring (active surveillance) and therefore lead to increased prostate cancer mortality. However, relabeling GG1 prostate cancer also reduces overdiagnosis and overtreatment, and given that these are the major disincentives to prostate-specific antigen (PSA) screening, it should increase use of prostate cancer screening and thereby reduce deaths from prostate cancer. OBJECTIVE: To model the effects of relabeling of GG1 prostate cancer on prostate cancer mortality in the US. DESIGN, SETTING, AND PARTICIPANTS: In this decision analytical model created in 2025, the number of men with GG1 cancer and those considering prostate cancer screening with prostate-specific antigen were estimated using US population-based and clinical data published from 2020 to 2025. EXPOSURE: Relabeling GG1 as a precancerous condition. MAIN OUTCOMES AND MEASURES: Predicted increase in prostate cancer deaths due to lower adherence with active surveillance vs predicted decrease in prostate cancer deaths due to higher screening rates related to reduced concerns regarding overdiagnosis and overtreatment. RESULTS: In the base case, which was relatively conservative, relabeling would lead to 6-fold more annual prostate deaths avoided than caused (2835 vs 452). Numerous scenarios modifying model inputs failed to change this conclusion. For instance, even if active surveillance progression rate increased by 50%, nonadherence rate doubled, and there was only a 10% absolute increase in screening, annual deaths would be reduced by close to 500. Under the base case, there would be a net decrease in mortality even if the absolute increase in screening rates was only 3%. CONCLUSIONS AND RELEVANCE: In this study, dropping the cancer label from GG1 prostate disease and redefining GG1 prostate disease as a precancerous lesion led to a net reduction in estimated prostate cancer deaths. Proponents for retaining the cancer label for GG1 prostate disease should argue relabeling would have close to zero effects on screening rates or that other harms outweigh the benefits of reduced prostate cancer mortality.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Vickers AJ, Cooperberg M, Pavlovich CP, et al. Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous. JAMA Oncol. 2026. PMID: 42166158. doi:10.1001/jamaoncol.2026.1391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。